FINCH 4 filgotinib RA extension study completes, results posted after long-term run

This week's update centers on the completion of a long-running rheumatoid arthritis extension study for filgotinib.

• FINCH 4 (NCT03025308) is described as a Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects With Rheumatoid Arthritis¹, sponsored by Alfasigma S.p.A. with Gilead Sciences as a collaborator. The study included both a Blinded Phase with Filgotinib 200 mg or 100 mg arms plus placebo to match, and an Open Label Phase with Filgotinib 200 mg or 100 mg arms, each for up to 6 years¹. The study is listed as completed, having started 2017-02-28 and reached primary and study completion on 2025-05-16¹, with enrollment of 2731 participants¹ and results first posted on 2026-07-27.